Abstract:Systemic sclerosis is an autoimmune disease leading to vasculopathy and fibrosis of skin and internal organs. Despite likely shared pathogenic mechanisms, the patterns of skin and lung fibrosis differ. Pathogenesis of interstitial lung disease, a major cause of death in systemic sclerosis, reflects the intrinsic disease pathobiology and is associated with distinct clinical phenotypes and laboratory characteristics. The commonest histological pattern of systemic sclerosis–interstitial lung disease is non-specific interstitial pneumonia. Systemic sclerosis–interstitial lung disease pathogenesis involves multiple components, including susceptibility and triggering factors, which could be genetic or environmental. The process is amplified likely through ongoing inflammation and the link between inflammatory activity and fibrosis with IL6 emerging as a key mediator. The disease is driven by epithelial injury, reflected by markers in the serum, such as surfactant proteins and KL-6. In addition, mediators that are produced by epithelial cells and that regulate inflammatory cell trafficking may be important, especially CCL2. Other factors, such as CXCL4 and CCL18, point towards immune-mediated damage or injury response. Monocytes and alternatively activated macrophages appear to be important. Transforming growth factor beta appears central to pathogenesis and regulates epithelial repair and fibroblast activation. Understanding pathogenesis may help to unravel the stages of systemic sclerosis–interstitial lung disease, risks of progression and determinants of outcome. With this article, we set out to review the multiple factors, including genetic, environmental, cellular and molecular, that may be involved in the pathogenesis of systemic sclerosis–interstitial lung disease and the mechanisms leading to sustained fibrosis. We propose a model for the pathogenesis of systemic sclerosis–interstitial lung disease, based on the available literature.

Connective Tissue Disease-Related Interstitial Lung Disease: Prevalence, Patterns, Predictors, Prognosis, and Treatment

Prevalence, imaging patterns and risk factors of interstitial lung disease in connective tissue disease: a systematic review and meta-analysis

Novel Therapeutic Approaches in Connective Tissue Disease-Associated Interstitial Lung Disease

Diagnostic Approach to Interstitial Lung Diseases Associated with Connective Tissue Diseases

A novel take on idiopathic pulmonary fibrosis disease progression: localised autoimmunity

Clinical characteristics of patients with connective tissue disease–related interstitial lung disease: a retrospective analysis

Interstitial Lung Disease in Systemic Lupus Erythematosus and Systemic Sclerosis: How Can We Manage the Challenge?

Clinically Relevant Biomarkers in Connective Tissue Disease-Associated Interstitial Lung Disease

Pathogenesis of systemic sclerosis associated interstitial lung disease

Pathogenesis of interstitial lung disease in systemic sclerosis

Cardiovascular disease in connective tissue disease-associated interstitial lung disease: A systematic review and meta-analysis of observational studies

Lung imaging patterns in connective tissue disease–associated interstitial lung disease impact prognosis and immunosuppression response

Interdisciplinary Diagnosis and Management of Patients With Interstitial Lung Disease and Connective Tissue Disease

Interstitial Lung Disease Associated with Systemic Sclerosis

Interstitial lung disease in Systemic sclerosis: insights into pathogenesis and evolving therapies

Chest high-resolution computed tomography in patients with connective tissue disease: pulmonary conditions beyond "the usual suspects"

Sexual Dimorphism in Interstitial Lung Disease

Role of Autoantibodies in the Diagnosis of Connective-Tissue Disease ILD (CTD-ILD) and Interstitial Pneumonia with Autoimmune Features (IPAF)

Connective tissue diseases, multimorbidity and the ageing lung

Lung Cancer and Interstitial Lung Diseases